. Author manuscript; available in PMC: 2012 Nov 29.

Published in final edited form as: Ann Oncol. 2009 Nov 4;21(1):98–103. doi: 10.1093/annonc/mdp496

Table 2.

Median survival and percent of cured mice after first line treatment

Xenograft	Treatment	Median^a	Benefit^b	Tumor-free mice %
BxPC-3	Control	55^b		0
	Gemcitabine	88	+33	0
	2mAbs	109	+54	33 (3/9)

MiaPaCa-2	Control	81		0
	Gemcitabine	94	+13	0
	2mAbs	122	+41	22 (2/9)

Capan-1	Control	44		0
	Gemcitabine	48	+4	0
	2mAbs	105	+61	20 (2/10)

Median: days post-graft where 50% of the mice present a 1000 mm³ tumor volume

Benefit: gain in days of the treatment vs control group